A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin

Primary Objective: To demonstrate noninferiority of Toujeo versus \"standard of care\" basal insulin therapy measured as glycosylated hemoglobin (HbA1c) change Secondary Objectives: * To demonstrate superiority of Toujeo versus \"standard of care\" basal insulin if noninferiority is met, measured as HbA1c change. * To compare Toujeo to other \"standard of care\" basal insulin in terms of patient persistence with assigned basal insulin therapy with or without intensification. * Risk of hypoglycemia including the incidence of documented symptomatic or severe hypoglycemic events \[as defined by the American Diabetes Association (ADA\] Workgroup on Hypoglycemia). * Change in fasting plasma glucose (FPG). * Change in body weight. * Differences in patient reported outcomes measured by Diabetes Treatment Satisfaction Questionnaire Status and Change Versions (DTSQs and DTSQc). * Change in hypoglycemic control subscale (HCS) * Healthcare resource utilization including hospitalizations and emergency department or other health care provider visits and healthcare costs.